SavedAdd your journal

Journals / Türk Oftalmoloji Dergisi / 2020 / Cilt: 50 - Sayı: 5

Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration

Anti-Vasküler Endotelyal Büyüme Faktörü TedavisineZayıf Cevap Veren Neovasküler Yaşa Bağlı MakülaDejenerasyonu Alt Grupları ve Özellikleri

Filiz AFRASHI
Serhad NALÇAÇI
Mine Esen BARIŞ
Cezmi AKKIN
Jale MENTEŞ
Pages
275–282
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Pigment epithelial detachment (PED) and occult choroidal neovascularization(CNV) were more common among poor responders (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascularage-related macular degeneration (nvAMD) and to define subgroups of poor responders.
📊
Key Findings & Data:Materials and Methods: A total of 235 treatment-naive eyes of 202 patients completed this prospective study.
💡
Conclusion & Impact:Pigment epithelial detachment (PED) and occult choroidal neovascularization(CNV) were more common among poor responders (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascularage-related macular degeneration (nvAMD) and to define subgroups of poor responders. Materials and Methods: A total of 235 treatment-naive eyes of 202 patients completed this prospective study. Patients youngerthan 50 years of age and those with a contraindication for anti-VEGF therapy were excluded. All eyes were treated with IV ranibizumab.Poor response was defined as recurrence, persistence, or worsening despite treatment. Poor responders were classified into subgroupsbased on progression patterns. Results: Of the 235 eyes, 78 (33.2%) showed poor response. Pigment epithelial detachment (PED) and occult choroidal neovascularization(CNV) were more common among poor responders (p

Özet

Amaç: Bu çalışma, aktif neovasküler yaşa bağlı maküla dejenerasyonunda (nvYBMD) intravitreal (İV) anti-vasküler endotelyal büyüme faktörü (anti-VEGF) tedavisine yetersiz cevap sıklığını belirlemeyi ve yetersiz cevap veren gözlerin alt gruplarını tanımlamayı amaçlamaktadır.Gereç ve Yöntem: Bu prospektif çalışmaya, daha önce hiç tedavi uygulanmamış olan 202 hastaya ait 235 göz dahil edilmiştir. Elli yaşından genç olan hastalar ve İV anti-VEGF tedavisi için kontrendikasyonu olanlar çalışma dışı bırakılmıştır. Tüm gözler ranibizumab ile tedavi edilmiştir. Tedaviye rağmen nüks, persistans veya kötüleşme görülmesi “yetersiz cevap” olarak kabul edilmiştir. Yetersiz cevap veren gözler, progresyon paternlerine göre alt gruplara ayrılmıştır.Bulgular: nvYBMD’li 235 gözün 78’i (%33,2) tedaviye yetersiz cevap vermiştir. Pigment epitel dekolmanı (PED) varlığı ve gizli koroidal neovaskülarizasyon (KNV) sıklığının tedaviye yetersiz cevap veren gözlerde istatistiksel olarak anlamlı oranda yüksek olduğu tespit edilmiştir (p

🔖

Cite This Article

AFRASHI, F., NALÇAÇI, S., BARIŞ, M. E., AKKIN, C., MENTEŞ, J. (2022). Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration. Türk Oftalmoloji Dergisi, Cilt: 50 - Sayı: 5, 275–282. https://ajindex.com/articles/637643

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850-857
  2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65
  3. Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, Ianchulev T; MARINA and ANCHOR Research Groups. Vision related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology. 2010;117:747-756
  4. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.N Engl J Med. 2011;364:1897-1908
  5. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, Tano Y, Wolf S. Ranibizumab (lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94:2-13
  6. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B; MARINA and ANCHOR Study Groups. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118:523-530
  7. Mariani A, Deli A, Ambresin A, Mantel I. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2011;249:1635-1642
  8. Shin JY, Woo SJ, Ahn J, Park KH. Anti-VEGF-refractory exudative agerelated macular degeneration: differential response according to features on optical coherence tomography. Korean J Ophthalmol. 2013;27:425-432
  9. Byun YJ, Lee SJ, Koh HJ. Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Jpn J Ophthalmol. 2010;54:571-577
  10. Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y. Defining response to anti-VEGF therapies in neovascular AMD. Eye (London). 2015;29:721-731
  11. Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Queré S, Schneider V; LUMIERE Study Group. Changes in visual acuit